⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955 | 0.80 | — | — | |
| SCHEMBL567044 | 0.80 | — | — | |
| SCHEMBL2198678 | 0.80 | — | — | |
| SCHEMBL7900423 | 0.77 | — | — | |
| SCHEMBL580950 | 0.75 | — | — | |
| SCHEMBL2499185 | 0.74 | — | — | |
| SCHEMBL4398004 | 0.74 | — | — | |
| SCHEMBL2330688 | 0.74 | — | — | |
| SCHEMBL16599556 | 0.74 | METAP1 (0.39) | — | |
| SCHEMBL5505561 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197489-A1 | COMPOSITION OF MATTER | ASTRAZENECA AB A SWEDISH CORPORATION | 2007-08-23 | — | — | US | claimed |
| EP-1032396-B1 | STERILIZATION OF GLUCOCORTICOSTEROIDS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | claimed |
| EP-0960139-B1 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | AVENTIS PHARMA INC (US) | 2004-02-04 | — | — | EP | claimed |
| US-20020065256-A1 | New composition of matter | ASTRAZENECA AB (SE) | 2002-05-30 | — | — | US | claimed |
| US-6392036-B1 | SANITIZING PARTICLES IN SAMPLE; OBTAIN SAMPLE, EXPOSE TO HEAT, MONITOR SAMPLE FOR ANTISEPTIC NATURE | ASTRAZENECA AB (CH) | 2002-05-21 | — | — | US | claimed |
| US-6248841-B1 | USING 2-MERCAPTOETHANOL | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-06-19 | — | — | US | claimed |
| US-6140308-A | ADMINISTERED TO A MAMMAL IN NEED FOR TREATMENT OF INFLAMED BOWEL MUCOSA A GLUCORTICOSTEROID-O-SUGAR EPIMERIC MIXTURE | AKTIEBOLAGET ASTRA (SE) | 2000-10-31 | — | — | US | claimed |
| EP-1043973-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT | AstraZeneca AB (SE) | 2000-10-18 | — | — | EP | claimed |
| EP-1032396-A1 | NEW COMPOSITION OF MATTER | Astrazeneca AB (SE) | 2000-09-06 | — | — | EP | claimed |
| WO-1999032089-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | claimed |
| WO-1999025359-A1 | NEW COMPOSITION OF MATTER | ASTRAZENECA AB (SE) | 1999-05-27 | — | — | WO | claimed |
| WO-1998033827-A9 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | — | 1998-12-30 | — | — | WO | claimed |
| EP-0793670-A1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES | RHONE-POULENC RORER LIMITED (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996031524-A1 | PROCESS FOR THE PREPARATION OF (20R)-16 ALPHA,17 ALPHA -BUTYLIDENEDIOXY-6 ALPHA,9 ALPHA-DIFLUORO-11 BETA-HYDROXY 17 BETA-(METHYLTHIO) ANDROST-4-3-ONE | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | claimed |
| WO-1996016978-A1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES | RHONE-POULENC RORER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| EP-0678097-A1 | NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1995-10-25 | — | — | EP | claimed |
| WO-1994015947-A1 | NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-07-21 | — | — | WO | claimed |
| EP-0502092-A1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES. | DRACO AB (SE) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007172-A1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | AKTIEBOLAGET DRACO (SE) | 1991-05-30 | — | — | WO | claimed |
| JP-1006291-A | — | — | None | — | — | JP | disclosed |
| US-9572802-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY LLC (US) | 2017-02-21 | — | — | US | disclosed |
| JP-5292905-B2 | — | — | 2013-09-18 | — | — | JP | disclosed |
| US-8431553-B2 | Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8017617-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1574222-B1 | Sterilization process for steroids | CIPLA LTD (IN) | 2011-02-09 | — | — | EP | disclosed |
| US-20100324002-A1 | Inhaled combination therapy | FOX JUSTIAN CRAIG | 2010-12-23 | — | — | US | disclosed |
| JP-2009263402-A | PRINTING INK AND METHOD FOR PRODUCING COATING FILM USING THE INK | MITSUBISHI MATERIALS CORP | 2009-11-12 | — | — | JP | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| US-7524834-B2 | Sterile powders, formulations, and methods for producing the same | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080318912-A1 | Medicaments for Treating Chronic Respiratory Disease | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20070197489-A1 | COMPOSITION OF MATTER | ASTRAZENECA AB A SWEDISH CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1133285-B1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | ASTRAZENECA AB (SE) | 2006-03-01 | — | — | EP | disclosed |
| US-20060025450-A1 | Use of an H+, K+ -ATPase inhibitor in the treatment of asthma | LINDBERG PER | 2006-02-02 | — | — | US | disclosed |
| EP-1574222-A1 | Sterilization process | Cipla Ltd. (IN) | 2005-09-14 | — | — | EP | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1032396-B1 | STERILIZATION OF GLUCOCORTICOSTEROIDS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-0960139-B1 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | AVENTIS PHARMA INC (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6599927-B2 | Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome | ASTRAZENECA AB (SE) | 2003-07-29 | — | — | US | disclosed |
| US-20030119859-A1 | Useful in the prophylaxis and treatment of respiratory diseases | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-0946175-B1 | USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS | ASTRAZENECA AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| US-6475524-B1 | Composition of matter | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| US-20020065256-A1 | New composition of matter | ASTRAZENECA AB (SE) | 2002-05-30 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-6392036-B1 | SANITIZING PARTICLES IN SAMPLE; OBTAIN SAMPLE, EXPOSE TO HEAT, MONITOR SAMPLE FOR ANTISEPTIC NATURE | ASTRAZENECA AB (CH) | 2002-05-21 | — | — | US | disclosed |
| US-6380222-B2 | WIDAL SYNDRONE; ASTHMA THERAPY | ASTRAZENECA AB (SE) | 2002-04-30 | — | — | US | disclosed |
| US-20010029255-A1 | Use of an H+, K+-ATPase inhibitor in the treatment of widal's syndrome | ASTRAZENA AB (SE) | 2001-10-11 | — | — | US | disclosed |
| EP-1133285-A1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| US-20010020014-A1 | Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps | SEAGATE TECHNOLOGY LLC | 2001-09-06 | — | — | US | disclosed |
| US-6248841-B1 | USING 2-MERCAPTOETHANOL | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-06-19 | — | — | US | disclosed |
| US-6183934-B1 | FOE USE IN FORMATION OF PATTERN OF INSULATION FILM, PASSIVATION FILM, .ALPHA.-RAY SHIELDING FILM, OPTICAL WAVEGUIDE | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-02-06 | — | — | US | disclosed |
| US-6140308-A | ADMINISTERED TO A MAMMAL IN NEED FOR TREATMENT OF INFLAMED BOWEL MUCOSA A GLUCORTICOSTEROID-O-SUGAR EPIMERIC MIXTURE | AKTIEBOLAGET ASTRA (SE) | 2000-10-31 | — | — | US | disclosed |
| EP-1043973-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT | AstraZeneca AB (SE) | 2000-10-18 | — | — | EP | disclosed |
| EP-1032396-A1 | NEW COMPOSITION OF MATTER | Astrazeneca AB (SE) | 2000-09-06 | — | — | EP | disclosed |
| EP-0960139-A4 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | RHONE POULENC RORER PHARMA (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000030614-A1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0960139-A1 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0946175-A1 | USE OF AN H+, K+ -ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS | Astra Aktiebolag (SE) | 1999-10-06 | — | — | EP | disclosed |
| US-5939409-A | CONDENSATION OF ALDEHYDE WITH STEROIDIOL TO FORM AN ACETAL GROUPS | ASTRA AKTIEBOLAG (SE) | 1999-08-17 | — | — | US | disclosed |
| WO-1999032089-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999025359-A1 | NEW COMPOSITION OF MATTER | ASTRAZENECA AB (SE) | 1999-05-27 | — | — | WO | disclosed |
| US-5888995-A | ANTIINFLAMMATORY AND ANTIALLERGENIC AGENTS; A NOVEL GLUCOCORTICOSTEROID | ASTRA AKTIEBOLAG (SE) | 1999-03-30 | — | — | US | disclosed |
| WO-1998033827-A9 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998033827-A1 | ELASTOMER TREATMENT PROCESS TO DECREASE PEROXIDE LEVELS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5756650-A | COMPOSITION COMPRISING POLYAMIC ACID, CURE ACCELERATOR SELECTED FROM GROUP CONSISTING OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AMINO ACID COMPOUND, AROMATIC COMPOUND HAVING TWO OR MORE HYDROXYL GROUPS | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-05-26 | — | — | US | disclosed |
| WO-1998016228-A1 | USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS | ASTRA AKTIEBOLAG (SE) | 1998-04-23 | — | — | WO | disclosed |
| EP-0793670-A1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES | RHONE-POULENC RORER LIMITED (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996031524-A1 | PROCESS FOR THE PREPARATION OF (20R)-16 ALPHA,17 ALPHA -BUTYLIDENEDIOXY-6 ALPHA,9 ALPHA-DIFLUORO-11 BETA-HYDROXY 17 BETA-(METHYLTHIO) ANDROST-4-3-ONE | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | disclosed |
| US-5556964-A | Process for the manufacture of budesonide | AKTIEBOLAGET ASTRA (SE) | 1996-09-17 | — | — | US | disclosed |
| WO-1996016978-A1 | PROCESS FOR THE PREPARATION OF STEROID DERIVATIVES | RHONE-POULENC RORER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| EP-0678097-A1 | NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES | AKTIEBOLAGET ASTRA (SE) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994015947-A1 | NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994013690-A1 | NEW STEROIDS | RHONE-POULENC RORER LIMITED (GB) | 1994-06-23 | — | — | WO | disclosed |
| EP-0572451-A1 | NOVEL STEROID ESTERS | Astra Aktiebolag (SE) | 1993-12-08 | — | — | EP | disclosed |
| EP-0570454-A1 | NOVEL STEROIDS | Astra Aktiebolag (SE) | 1993-11-24 | — | — | EP | disclosed |
| US-5215979-A | Antiinflammatory agents; antiallergens | AKTIEBOLAGET DRACO (SE) | 1993-06-01 | — | — | US | disclosed |
| EP-0502092-A1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES. | DRACO AB (SE) | 1992-09-09 | — | — | EP | disclosed |
| WO-1992013872-A1 | NOVEL STEROIDS | AKTIEBOLAGET ASTRA (SE) | 1992-08-20 | — | — | WO | disclosed |
| EP-0262108-B1 | A METHOD OF CONTROLLING THE EMPIMERIC DISTRIBUTION IN THE PREPARATION OF 16,17-ACETALS OR KETALS OF PREGNANE DERIVATIVES | Astra Pharmaceutical Production AB (SE) | 1991-12-04 | — | — | EP | disclosed |
| WO-1991007172-A1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | AKTIEBOLAGET DRACO (SE) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991004984-A1 | PROCESS FOR THE MANUFACTURE OF BUDESONIDE | AKTIEBOLAGET ASTRA (SE) | 1991-04-18 | — | — | WO | disclosed |
| JP-S646291-A | 21-SUBSTITUTED STEROID COMPOUND | TAISHO PHARMACEUTICAL CO LTD | 1989-01-10 | — | — | JP | disclosed |
| EP-0262108-A1 | A method of controlling the empimeric distribution in the preparation of 16,17-acetals or ketals of pregnane derivatives | Astra Pharmaceutical Production AB (SE) | 1988-03-30 | — | — | EP | disclosed |
| US-4229466-A | TREATING NEPHRITIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-21 | — | — | US | disclosed |
| US-4229466-A | TREATING NEPHRITIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-21 | — | — | US | disclosed |